semaglutide · Novo · NDA 215256
Wegovy Hd
Earliest generic entry, as listed
17 Feb 2041
Blocked by patent: US 11318191.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11318191 | product, use U-4418 | 17 Feb 2041 |
| US 12029779 | use U-4418 | 10 Oct 2038 |
| US 12551536 | use U-4418 | 10 Oct 2038 |
| US 10888605 | product, use U-4418 | 24 Aug 2038 |
| US 11752198 | product, use U-4418 | 24 Aug 2038 |
| US 12214017 | product, use U-4418 | 24 Aug 2038 |
| US 9764003 | use U-4418 | 21 Jun 2033 |
| US 8129343 | substance, product | 5 Dec 2031 |
Exclusivities · 1 unexpired
| NS | new strength | 19 Mar 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215256 · 006 · RLD | solution, subcutaneous | 7.2MG/0.75ML (7.2MG/0.75ML) | 17 Feb 2041 |